LU71739A1 - - Google Patents

Info

Publication number
LU71739A1
LU71739A1 LU71739A LU71739A LU71739A1 LU 71739 A1 LU71739 A1 LU 71739A1 LU 71739 A LU71739 A LU 71739A LU 71739 A LU71739 A LU 71739A LU 71739 A1 LU71739 A1 LU 71739A1
Authority
LU
Luxembourg
Application number
LU71739A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU71739A1 publication Critical patent/LU71739A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU71739A 1974-01-29 1975-01-28 LU71739A1 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7402810A FR2258841B1 (enExample) 1974-01-29 1974-01-29

Publications (1)

Publication Number Publication Date
LU71739A1 true LU71739A1 (enExample) 1975-06-24

Family

ID=9134107

Family Applications (1)

Application Number Title Priority Date Filing Date
LU71739A LU71739A1 (enExample) 1974-01-29 1975-01-28

Country Status (6)

Country Link
BE (1) BE824885A (enExample)
DE (1) DE2503136A1 (enExample)
FR (1) FR2258841B1 (enExample)
GB (1) GB1495665A (enExample)
LU (1) LU71739A1 (enExample)
NL (1) NL7500613A (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
JP5941916B2 (ja) 2010-09-22 2016-06-29 アリーナ ファーマシューティカルズ, インコーポレイテッド Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
DK3242666T5 (da) 2015-01-06 2025-01-20 Arena Pharm Inc Forbindelsee til anvendelse i behandling af tilstande, der er forbundet med SIP1-receptoren
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1

Also Published As

Publication number Publication date
GB1495665A (en) 1977-12-21
FR2258841A1 (enExample) 1975-08-22
NL7500613A (nl) 1975-07-31
BE824885A (fr) 1975-07-28
DE2503136A1 (de) 1975-07-31
FR2258841B1 (enExample) 1977-11-04

Similar Documents

Publication Publication Date Title
FR2258327A1 (enExample)
FR2256180A1 (enExample)
FR2258841B1 (enExample)
AU495841B2 (enExample)
FI750998A7 (enExample)
FI144474A7 (enExample)
FR2258325B1 (enExample)
DK111175A (enExample)
FI52827B (enExample)
AU7462274A (enExample)
AU7459074A (enExample)
AU495870B2 (enExample)
CS166638B1 (enExample)
AU7099174A (enExample)
CH609586A5 (enExample)
BE830261A (enExample)
AU481423A (enExample)
BE332773A (enExample)
BE829575A (enExample)
BE830156A (enExample)
DD117796A1 (enExample)
CH614059A5 (enExample)
BG20454A1 (enExample)
CH604420A5 (enExample)
CH599166A5 (enExample)